Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655

European Journal of Human Genetics

Volumn 19, Issue 10, 2011, Pages 1100-1103

  Søndergaard, Helle Bach ^a   Sellebjerg, Finn ^a   Hillert, Jan ^b   Olsson, Tomas ^b   Kockum, Ingrid ^b   Lindén, Magdalena ^b   Mero, Inger Lise ^c   Myhr, Kjell Morten ^d,e   Celius, Elisabeth G ^c   Harbo, Hanne F ^c,f   Christensen, Jeppe Romme ^a   Börnsen, Lars ^a   Sørensen, Per Soelberg ^a   Oturai, Annette Bang ^a  

^a Rigshospitalet   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

association study; casecontrol study; CD161; KLRB1; multiple sclerosis

Indexed keywords

BETA1A INTERFERON; CD161 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DENMARK; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NORWAY; PATHOGENESIS; PRIORITY JOURNAL; SCANDINAVIA; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MULTIPLE SCLEROSIS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; POLYMORPHISM, SINGLE NUCLEOTIDE; SCANDINAVIA;

EID: 80053053910     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2011.88     Document Type: Article

References (23)

1. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L: Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009; 73: 696-701.
2. Ebers GC: Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7: 268-277. (Pubitemid 351222732)
3. Oksenberg JR, Baranzini SE: Multiple sclerosis genetics-is the glass half full, or half empty? Nat Rev Neurol 2010; 6: 429-437.
4. Jersild C, Fog T, Svejgaard A: Hl-A antigens and multiple-sclerosis. Lancet 1972; 1: 1240.
5. Bush WS, Sawcer SJ, De Jager PL, et al. Evidence for polygenic susceptibility to multiple sclerosis-the shape of things to come. Am J Hum Genet 2010; 86: 621-625.
6. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862. (Pubitemid 47347319)
7. Lanier LL, Chang C, Phillips JH: Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994; 153: 2417-2428. (Pubitemid 24278110)
8. Cosmi L, De Palma R, Santarlasci V, et al. Human interleukin 17-producing cells originate from a CD161(+)CD4(+) T cell precursor. J Exp Med 2008; 205: 1903-1916.
9. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S: Functions of natural killer cells. Nat Immunol 2008; 9: 503-510. (Pubitemid 351560519)
10. Rosen DB, Cao W, Avery DT, et al. Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells. J Immunol 2008; 180: 6508-6517.
11. Aldemir H, Prodhomme V, Dumaurier MJ, et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 2005; 175: 7791-7795. (Pubitemid 41798337)
12. Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL: Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 2005; 175: 7796-7799. (Pubitemid 41798338)
13. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005; 58: 840-846. (Pubitemid 41746873)
14. Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F: Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008; 14: 622-630. (Pubitemid 351954404)
15. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
16. Novembre J, Johnson T, Bryc K, et al. Genes mirror geography within Europe. Nature 2008; 456: 98-101.
17. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575. (Pubitemid 47330214)
18. Hesse D, Krakauer M, Lund H, et al. Breakthrough disease during interferon-[beta] therapy in MS: no signs of impaired biologic response. Neurology 2010; 74: 1455-1462.
19. De Jager PL, Rossin E, Pyne S, et al. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8(low) cells. Brain 2008; 131: 1701-1711. (Pubitemid 351957464)
20. Sellebjerg F, Ross C, Koch-Henriksen N, et al. CD26+ CD4+ T cell counts and attack risk in interferon-treated multiple sclerosis. Mult Scler 2005; 11: 641-645. (Pubitemid 41685133)
21. Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T: The regulatory role of natural killer cells in multiple sclerosis. Brain 2004; 127: 1917-1927. (Pubitemid 39150251)
22. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 5941-5946.
23. Johansson S, Berg L, Hall H, Hoglund P: NK cells: elusive players in autoimmunity. Trends Immunol 2005; 26: 613-618. (Pubitemid 41726450)